Current knowledge of ductal carcinoma in situ


Authors: J. Böhm 1;  M. Zikán 2
Authors‘ workplace: Gynekologicko-porodnické oddělení, klinika MEDINOS, Sonneberg, SRN 1;  Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha 2
Published in: Ceska Gynekol 2009; 74(5): 339-347

Overview

Objective:
With respect to an increasing incidence of ductal carcinoma in situ (DCIS) of the breast and thus growing importance of this disease we want to review the current data about the diagnostics and therapy of this leasion. We will also try to outline the future development of the management of this disease.

Design:
Review article describing the current knowledge of ductal carcinoma in situ.

Setting:
Department of Gyneacology and Obstetrics, MEDINOS Clinic, Sonneberg, Germany.

Methods:
Study of the current literature.

Conclusion:
Evidence-based guidelines for therapy of this disease are still not available. Up-to-date management is based on the theory of linear progression, which means that DCIS is an obligate precursor of invasive breast carcinoma. Consequently, we treat this leasion vigorously in order to prevent future recurrences or invasive disease. Existing prognostic and predictive markers do not allow a sufficient classification of low-grade and high-grade patients. Further studies are necessary in order to distinguish women who need only an observation from those who require a full-scale therapy.

Key words:
ductal carcinoma in situ, therapy, prognostic and predictive factors.


Sources

1. Allred, DC., Mohsin, SK., Fuqua, SA. Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer, 2001, 8, 1, p. 47-61.

2. Allred, DC., Clark, GM., Molina, R., et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol, 1992, 23, 9, p. 974–979.

3. Ariga, N., Suzuki, T., Moriya, T., et al. Progesterone receptor A and B isoforms in the human breast and its disorders. Jpn J Cancer Res., 2001, 92, 3, p. 302–308.

4. Barnes, NL., Boland, GP., Davenport, A., et al. Relationship between hormone receptor status and tumour size, grade and comedo necrosis in ductal carcinoma in situ. Br J Surg, 2005, 92, 4, p. 429–434.

5. Bergstraesser, LM., Srinivasan, G., Jones, JC., et al. Expression of hemidesmosomes and component proteins is lost by invasive breast cancer cells. Am J Pathol., 1995, 147, 6, p. 1823-1839.

6. Bijker, N., Meijnen, P., Peterse, JL., et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol, 2006, 24, 21, p. 3381-2387.

7. Boughey, JC., Gonzalez, RJ., Bonner, E., et al. Current treatment and clinical trial developments for ductal carcinoma in situ of the breast. Oncologist, 2007, 12, 11, p. 1276-1287.

8. Collins, LC., Tamimi, RM., Baer, HJ., et al. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses’ Health Study. Cancer, 2005, 103, 9, p. 1778-1784.

9. Dixon, JM., Faratian, D., White, S., et al. DCIS and aromatase inhibitors. J Steroid Biochem Mol Biol, 2007, 106, 1-5, p. 173-179.

10. Edorh, A., Leroux, A., N’sossani, B., et al. Detection by immunohistochemistry of c-erbB2 oncoprotein in breast carcinomas and benign mammary lesions. Cell Mol Biol (Noisy-le-grand), 1999, 45, 6, p. 831–840.

11. Emdin, SO., Granstrand, B., Ringberg, A., et al. SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol, 2006, 45, 5, p. 536-543.

12. Ernster, VL., Ballard-Barbash, R., Barlow, WE., et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst, 2002, 94, 20, p. 1546-1554.

13. Eusebi, V., Feudale, E., Foschini, MP., et al. Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol., 1994, 11, 3, p. 223-235.

14. Farabegoli, F., Champeme, MH., Bieche, I., et al. Genetic pathways in the evolution of breast ductal carcinoma in situ. J Pathol, 2002, 196, 3, p. 280-286.

15. Fisher, B., Land, S., Mamounas, E., et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin Oncol, 2001, 28, 4, p. 400-418.

16. Georgian-Smith, D., Lawton, TJ. Calcifications of lobular carcinoma in situ of the breast: radiologic-pathologic correlation. Am J Roentgenol, 2001, 176, 5, p. 1255-1259.

17. Gilleard, O., Goodman, A., Cooper, M., et al. The significance of the Van Nuys prognostic index in the management of ductal carcinoma in situ. World J Surg Oncol, 2008, 18, 6, p. 61.

18. Gobbi, H., Dupont, WD., Simpson, JF., et al. Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia. J Natl Cancer Inst, 1999, 91, 24, 2096–2101.

19. Gonzalez, RJ., Buzdar, AU., Fraser Symmans, W., et al. Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin). Breast J, 2007, 13, 1, p. 72-75.

20. Gupta, SK., Douglas-Jones, AG., Jasani, B., et al. E-cadherin (E-cad) expression in duct carcinoma in situ (DCIS) of the breast. Virchows Arch, 1997, 430, 1, p. 23–28.

21. Hieken, TJ., Farolan, M., D’Alessandro, S., et al. Predicting the biologic behavior of ductal carcinoma in situ: an analysis of molecular markers. Surgery, 2001, 130, 4, p. 593–600.

22. Houghton, J., George, WD., Cuzick, J., et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet, 2003, 362, 9378, p. 95-102.

23. Hwang, ES., Esserman, L. Neoadjuvant hormonal therapy for ductal carcinoma in situ: trial design and preliminary results. Ann Surg Oncol, 2004, 11, 1, příloha, p. 37S-43S.

24. Hwang, ES., McLennan, JL., Moore, DH., et al. Ductal carcinoma in situ in BRCA mutation carriers. J Clin Oncol, 2007, 25, 6, p. 642-647.

25. Iqbal, M., Davies, MP., Shoker, BS., et al. Subgroups of non-atypical hyperplasia of breast defined by proliferation of oestrogen receptor-positive cells. J Pathol, 2001, 193, 3, p. 333–338.

26. Keohavong, P., Gao, WM., Mady, HH., et al. Analysis of p53 mutations in cells taken from paraffin-embedded tissue sections of ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Cancer Lett, 2004, 212, 1, p. 121–130.

27. Khan, SA., Rogers, MA., Khurana, KK., et al. Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst., 1998, 90, 1, p. 37-42.

28. Lakhani, SR., Collins, N., Stratton, MR., et al. Atypical ductal hyperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p. J Clin Pathol, 1995, 48, p. 611–615.

29. Middleton, LP., Palacios, DM., Bryant, BR., et al. Pleomorphic lobular carcinoma: morphology, immunohistochemistry, and molecular analysis. Am J Surg Pathol, 2000, 24, 12, p. 1650-1656.

30. Mote, PA., Bartow, S., Tran, N., et al. Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis. Breast Cancer Res Treat, 2002, 72, 2, p. 163–172.

31. Mote, PA., Leary, JA., Avery, KA., et al. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A. Genes Chromosomes Cancer, 2004, 39, 3, p. 236–248.

32. Murphy, CD., Jones, JL., Javid, SH., et al. Do sentinel node micrometastases predict recurrence risk in ductal carcinoma in situ and ductal carcinoma in situ with microinvasion? Am J Surg, 2008, 196, 4, p. 566-568.

33. Mustonen, M., Raunio, H., Pääkkö, P., et al. The extent of apoptosis is inversely associated with bcl-2 expression in premalignant and malignant breast lesions. Histopathology, 1997, 31, 4, p. 347-354.

34. O’Connell, P., Pekkel, V., Fuqua, SA., et al. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst, 1998, 90, 9, p. 697-703.

35. Oh, YL., Choi, JS., Song, SY., et al. Expression of p21Waf1, p27Kip1 and cyclin D1 proteins in breast ductal carcinoma in situ: Relation with clinicopathologic characteristics and with p53 expression and estrogen receptor status. Pathol Int, 2001, 51, 2, p. 94-99.

36. O’Malley, FP., Vnencak-Jones, CL., Dupont, WD., et al. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data. Lab Invest, 1994, 71, 1, p. 67–72.

37. Page, DL., Dupont, WD., Rogers, LW., et al. Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer, 1982, 49, 4, p. 751-758.

38. Page, DL., Schuyler, PA., Dupont, WD., et al. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet, 2003, 361, 9352, p. 125-129.

39. Paik, S., Shak, S., Tang, G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med, 2004, 351, 27, p. 2817-2826.

40. Provenzano, E., Hopper, JL., Giles, GG., et al. Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast. Eur J Cancer, 2003, 39, 5, p. 622–630.

41. Raju, U., Lu, M., Sethi, S., et al. Molecular classification of breast carcinoma in situ. Curr Genomics, 2006, 7, 8, p. 523-532.

42. Reynolds, PA., Smolen, GA., Palmer, RE., et al. Identification of a DNA-binding site and transcriptional target for the EWS-WT1(+KTS) oncoprotein. Genes Dev, 2003, 17, 17, p. 2094-2107.

43. Rosen, PP., Braun, DW. Jr, Kinne, DE. The clinical significance of pre-invasive breast carcinoma. Cancer, 1980, 15, 46, p. 919-925.

44. Rosner, D., Bedwani, RN., Vana, J., et al. Noninvasive breast carcinoma: results of a national survey by the American College of Surgeons. Ann Surg, 1980, 192, 2, p. 139-147.

45. Sakr, R., Bezu, C., Raoust, I., et al. The sentinel lymph node procedure for patients with preoperative diagnosis of ductal carcinoma in situ: risk factors for unsuspected invasive disease and for metastatic sentinel lymph nodes. Int J Clin Pract, 2008, 62, 11, p. 1730-1735.

46. Sanders, ME., Schuyler, PA., Dupont, WD., et al. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer, 2005, 103, 12, p. 2481-2484.

47. Sasaki, H., Yu, CY., Dai, M., et al. Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer. Breast Cancer Res Treat, 2003, 77, 3, p. 245-252.

48. Satoh, K., Hata, M., Yokota, H. High lib mRNA expression in breast carcinomas. DNA Res, 2004, 11, 3, p. 199-203.

49. Shaaban, AM., Jarvis, C., Moore, F., et al. Prognostic significance of estrogen receptor Beta in epithelial hyperplasia of usual type with known outcome. Am J Surg Pathol, 2005, 29, 12, p. 1593–1599.

50. Shao, R., Bao, S., Bai, X., et al. Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Mol Cell Biol, 2004, 24, 9, p. 3992-4003.

51. Shoker, BS., Jarvis, C., Clarke, RB., et al. Estrogen receptor-positive proliferating cells in the normal and precancerous breast. Am J Pathol, 1999, 155, 6, p. 1811-1815.

52. Silverstein, MJ., Lagios, MD., Craig, PH., et al. A prognostic index for ductal carcinoma in situ of the breast. Cancer, 1996, 77, 11, p. 2267-2274.

53. Silverstein, MJ., Lagios, MD., Groshen, S., et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med, 1999, 340, 19, p. 1455-1461.

54. Smith, KL., Adank, M., Kauff, N., et al. BRCA mutations in women with ductal carcinoma in situ. Clin Cancer Res, 2007, 13, 14, p. 4306-4310.

55. Stark, A., Hulka, BS., Joens, S., et al. HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. J Clin Oncol, 2000, 18, 2, p. 267–274.

56. Tavassoli, FA., Devilee, P., World Health Organization Classification of Tumours. Pathology & Genetics of Tumours of the Breast and Female Genital Organs, 1. ed. Lyon : IARC Press, 2003, p. 69-70.

57. Tsuda, H., Iwaya, K., Fukutomi, T., et al. p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade. Jpn J Cancer Res, 1993, 84, 4, p. 394–401.

58. Umbricht, CB., Evron, E., Gabrielson, E., et al. Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene, 2001, 20, 26, p. 3348–3353.

59. Viacava, P., Naccarato, AG., Bevilacqua, G., et al. Different proliferative patterns characterize different preinvasive breast lesions. J Pathol, 1999, 188, 3, p. 245–251.

60. Viacava, P., Naccarato, AG., Bocci, G., et al. Angiogenesis and VEGF expression in pre-invasive lesions of the human breast. J Pathol, 2004, 204, 2, p. 140–146.

61. Vieira, CC., Mercado, CL., Cangiarella, JF., et al. Microinvasive ductal carcinoma in situ: Clinical presentation, imaging features, pathologic findings, and outcome [Epub ahead of print] Eur J Radiol, 2008 Nov 19.

62. Walker, RA., Dearing, SJ. Transforming growth factor beta 1 in ductal carcinoma in situ and invasive carcinomas of the breast. Eur J Cancer, 1992, 28, 2-3, p. 641–644.

63. Wong, JS., Kaelin, CM., Troyan, SL., et al. Prospective study of width excision alone for ductal carcinoma in situ of the breast. J Clin Oncol, 2006, 24, 7, p. 1031-1036.

64. Xu, R., Perle, MA., Inghirami, G., et al. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Mod Pathol, 2002, 15, 2, p. 116–124.

65. Zagouri, F., Sergentanis, TN., Zografos, GC. Precursors and preinvasive lesions of the breast: the role of molecular prognostic markers in the diagnostic and therapeutic dilemma. World J Surg Oncol, 2007, 5, 57.

Labels
Paediatric gynaecology Gynaecology and obstetrics Reproduction medicine
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account